In a report released on April 15, Shagun Singh Chadha from RBC Capital maintained a Hold rating on Outset Medical (OM – Research Report), with a price target of $5.00. The company’s shares closed yesterday at $2.08.
According to TipRanks, Singh Chadha is a 2-star analyst with an average return of -0.4% and a 42.05% success rate. Singh Chadha covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Boston Scientific, and Abbott Labs.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Outset Medical with a $6.40 average price target.
Based on Outset Medical’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $30.51 million and a GAAP net loss of $38.6 million. In comparison, last year the company earned a revenue of $32.01 million and had a GAAP net loss of $41.44 million
Based on the recent corporate insider activity of 76 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of OM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Outset Medical (OM) Company Description:
Outset Medical Inc is a medical technology company. The company has developed a machine, Tablo, which reduces the cost and complexity of dialysis.
Read More on OM:
- Outset Medical initiated with a Buy at BTIG
- Outset Medical upgraded to Buy from Neutral at CL King
- Outset Medical Board Changes: New Director Appointed, Szyman Steps Down
- Novo FLOW trial results positive for Outset Medical, says RBC Capital
- Outset Medical affirms FY24 revenue view of $145M-$153M, consensus $148.8M
